BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36683274)

  • 1. In silico identification and biological evaluation of a selective MAP4K4 inhibitor against pancreatic cancer.
    Chang CD; Chao MW; Lee HY; Liu YT; Tu HJ; Lien ST; Lin TE; Sung TY; Yen SC; Huang SH; Hsu KC; Pan SL
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2166039. PubMed ID: 36683274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAP4K4 promotes pancreatic tumorigenesis via phosphorylation and activation of mixed lineage kinase 3.
    Singh SK; Kumar S; Viswakarma N; Principe DR; Das S; Sondarva G; Nair RS; Srivastava P; Sinha SC; Grippo PJ; Thatcher GRJ; Rana B; Rana A
    Oncogene; 2021 Oct; 40(43):6153-6165. PubMed ID: 34511598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective protection of human cardiomyocytes from anthracycline cardiotoxicity by small molecule inhibitors of MAP4K4.
    Golforoush PA; Narasimhan P; Chaves-Guerrero PP; Lawrence E; Newton G; Yan R; Harding SE; Perrior T; Chapman KL; Schneider MD
    Sci Rep; 2020 Jul; 10(1):12060. PubMed ID: 32694738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuritogenic militarinone-inspired 4-hydroxypyridones target the stress pathway kinase MAP4K4.
    Schröder P; Förster T; Kleine S; Becker C; Richters A; Ziegler S; Rauh D; Kumar K; Waldmann H
    Angew Chem Int Ed Engl; 2015 Oct; 54(42):12398-403. PubMed ID: 25908259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4.
    Zhao G; Wang B; Liu Y; Zhang JG; Deng SC; Qin Q; Tian K; Li X; Zhu S; Niu Y; Gong Q; Wang CY
    Mol Cancer Ther; 2013 Nov; 12(11):2569-80. PubMed ID: 24013097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulated miR-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4.
    Fu Y; Liu X; Chen Q; Liu T; Lu C; Yu J; Miao Y; Wei J
    J Exp Clin Cancer Res; 2018 Jul; 37(1):130. PubMed ID: 29970191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
    Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
    Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology.
    Kharbanda A; Tran P; Zhang L; Leung YK; Li HY; Frett B
    Eur J Med Chem; 2021 Dec; 225():113763. PubMed ID: 34419892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma.
    Liang JJ; Wang H; Rashid A; Tan TH; Hwang RF; Hamilton SR; Abbruzzese JL; Evans DB; Wang H
    Clin Cancer Res; 2008 Nov; 14(21):7043-9. PubMed ID: 18981001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells.
    Yu C; Zhang X; Sun G; Guo X; Li H; You Y; Jacobs JL; Gardner K; Yuan D; Xu Z; Du Q; Dai C; Qian Z; Jiang K; Zhu Y; Li QQ; Miao Y
    J Cell Mol Med; 2008 Dec; 12(6A):2334-49. PubMed ID: 18266952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer.
    Pan Y; Zheng M; Zhong L; Yang J; Zhou S; Qin Y; Xiang R; Chen Y; Yang SY
    Mol Cancer Ther; 2015 Feb; 14(2):407-18. PubMed ID: 25519702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAP4K4 mediates the SOX6-induced autophagy and reduces the chemosensitivity of cervical cancer.
    Huang H; Han Q; Zheng H; Liu M; Shi S; Zhang T; Yang X; Li Z; Xu Q; Guo H; Lu F; Wang J
    Cell Death Dis; 2021 Dec; 13(1):13. PubMed ID: 34930918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming radioresistance of breast cancer cells with MAP4K4 inhibitors.
    Kwon YS; Lee MG; Kim NY; Nam GS; Nam KS; Jang H; Kim S
    Sci Rep; 2024 Mar; 14(1):7410. PubMed ID: 38548749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance.
    Gao X; Chen G; Gao C; Zhang DH; Kuan SF; Stabile LP; Liu G; Hu J
    Mol Oncol; 2017 Jun; 11(6):628-639. PubMed ID: 28306189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-based identification and optimization of a class of potent pyrrolo[2,1-f][1,2,4]triazine MAP4K4 inhibitors.
    Wang L; Stanley M; Boggs JW; Crawford TD; Bravo BJ; Giannetti AM; Harris SF; Magnuson SR; Nonomiya J; Schmidt S; Wu P; Ye W; Gould SE; Murray LJ; Ndubaku CO; Chen H
    Bioorg Med Chem Lett; 2014 Sep; 24(18):4546-4552. PubMed ID: 25139565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
    Huang M; Huang Y; Guo J; Yu L; Chang Y; Wang X; Luo J; Huang Y; Tu Z; Lu X; Xu Y; Zhang Z; Zhang Z; Ding K
    Eur J Med Chem; 2021 Feb; 211():113023. PubMed ID: 33248853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer.
    Kandil SB; Jones SR; Smith S; Hiscox SE; Westwell AD
    Molecules; 2020 Jul; 25(15):. PubMed ID: 32751931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.
    Azzariti A; Bocci G; Porcelli L; Fioravanti A; Sini P; Simone GM; Quatrale AE; Chiarappa P; Mangia A; Sebastian S; Del Bufalo D; Del Tacca M; Paradiso A
    Br J Cancer; 2011 Mar; 104(5):769-80. PubMed ID: 21304529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based discovery of new maternal embryonic leucine zipper kinase inhibitors.
    Zhou S; Li GB; Luo L; Zhong L; Chen K; Li H; Jiang XJ; Fu Q; Long X; Bao JK
    Org Biomol Chem; 2018 Feb; 16(9):1489-1495. PubMed ID: 29411820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of selective 4-Amino-pyridopyrimidine inhibitors of MAP4K4 using fragment-based lead identification and optimization.
    Crawford TD; Ndubaku CO; Chen H; Boggs JW; Bravo BJ; Delatorre K; Giannetti AM; Gould SE; Harris SF; Magnuson SR; McNamara E; Murray LJ; Nonomiya J; Sambrone A; Schmidt S; Smyczek T; Stanley M; Vitorino P; Wang L; West K; Wu P; Ye W
    J Med Chem; 2014 Apr; 57(8):3484-93. PubMed ID: 24673130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.